THE SIGNIFICANCE OF MODERN BIOMARKERS IN EARLY CANCER DETECTION WITHIN CONTEMPORARY MEDICINE

Rustamov Jamol Istamovich
Teacher of the Department of General Medical Sciences, Navoi State University
G’iyosova Farida G’ayrat qizi
2nd year student of Pediatrics at Navoi State University

ABSTRACT: *Early detection of malignancies remains one of the most critical factors influencing cancer prognosis and patient survival. Modern biomarkers have revolutionized the landscape of oncological diagnostics, offering non-invasive or minimally invasive approaches to identify cancer at its earliest, most treatable stages. This comprehensive review examines the current state and future prospects of biomarker applications in early cancer detection. Traditional serum markers, while clinically useful, demonstrate limitations in sensitivity and specificity that restrict their utility primarily to disease monitoring rather than screening. Emerging technologies including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, microRNAs, and advanced multi-omics platforms are transforming diagnostic capabilities. Liquid biopsy approaches enable real-time tumor profiling without invasive tissue sampling, facilitating early intervention strategies. Despite significant technological advances, challenges persist including biomarker heterogeneity, standardization deficits, and limited accessibility in resource-constrained settings. This review synthesizes current evidence on traditional and emerging biomarkers, evaluates their clinical applications across major cancer types, and discusses innovative platforms such as wearable biosensors and cell-based assays that may redefine early detection paradigms. The integration of artificial intelligence with biomarker discovery and interpretation represents a promising frontier for personalized oncology. Future directions emphasize the need for rigorous validation studies, standardized protocols, and equitable implementation strategies to maximize the global impact of biomarker-based early cancer detection.*

Keywords: *early cancer detection, biomarkers, liquid biopsy, circulating tumor DNA, ctDNA, circulating tumor cells, precision oncology, cancer screening, multi-cancer early detection, tumor markers*

INTRODUCTION

Malignant diseases represent one of the most formidable challenges to global health, causing profound devastation to human life, emotions, hopes, resources, and economies. According to the World Health Organization, malignancies constitute the second leading

cause of death worldwide, following cardiovascular diseases, with approximately 20 million new cases and 10 million cancer-associated deaths reported in 2022 alone . The burden falls disproportionately on low-income countries, where cancer-related mortality rates are 75% higher due to poor health literacy, socioeconomic factors, and limited diagnostic accessibility, resulting in estimated economic losses exceeding one trillion dollars annually .

The accurate diagnosis of malignancy constitutes the first and most critical step in combating cancer. Malignant cells characteristically grow rapidly and metastasize to distant sites, making the disease significantly more difficult to treat at advanced stages. Tumor volume doubling times vary considerably across cancer types—from as brief as 24-48 hours for Burkitt's lymphoma to over two years for most prostate cancers—highlighting the urgency of early detection and underscoring the narrow window available for initiating effective treatment . Early diagnosis significantly improves patient outcomes: investigations demonstrate that early detection leads to median overall survival of 38 months compared to 14 months with delayed diagnosis, while quality of life scores increase from 55 to 75 and severe treatment-related side effects decrease from 45% to 18% .

Currently, the diagnosis of malignant diseases primarily relies on radiological findings and examination of patient tissue samples for signs of pathology. However, such approaches may be invasive, potentially harmful, and poorly suited for broad implementation across general populations. Consequently, many common malignancies—including lung, breast, and gastrointestinal cancers—are frequently diagnosed at advanced stages, thereby reducing the likelihood of successful radical treatment . To address this challenge and enable detection of early malignancies, non-invasive approaches such as determination of tumor-specific biomolecules or circulating tumor cells hold significant potential for early tumor discovery .

Biomarkers—biological molecules found in blood, other body fluids, or tissues that indicate normal or abnormal processes, conditions, or diseases—have emerged as perhaps the most promising tools for early cancer diagnosis. They objectively indicate molecular characteristics of cancer, enabling early diagnosis and disease management that results in improved patient prognosis . Beyond early detection, biomarkers play crucial roles in determining therapeutic options, predicting clinical outcomes, assessing patients for cancer risk estimation, screening for primary-stage cancers, prognosis prediction, monitoring disease status and treatment responses, detecting early signs of recurrence, distinguishing cancer types, and evaluating patient clinical outcomes .

This review aims to comprehensively examine the significance of modern biomarkers in early cancer detection within contemporary medicine. We evaluate both traditional protein markers and emerging genomic, epigenomic, and cellular biomarkers, assess their clinical applications across major cancer types, discuss innovative technological platforms, and

analyze challenges and future directions for biomarker implementation in diverse healthcare settings.

LITERATURE REVIEW

Historical Evolution of Cancer Biomarkers - The concept of using biological molecules for cancer detection dates back to 1847, when Bence Jones protein was identified in urine of multiple myeloma patients, marking the first recognized tumor marker . This discovery established the foundation for subsequent biomarker development throughout the twentieth century. The mid-1900s witnessed the identification of several classical markers that remain clinically relevant today: human chorionic gonadotropin (hCG) for germ cell tumors in 1956, alpha-fetoprotein (AFP) for hepatocellular carcinoma in 1963, and carcinoembryonic antigen (CEA) for colorectal cancer in 1965 . The 1970s and 1980s brought expansion of the biomarker armamentarium with discoveries including prostate-specific antigen (PSA) in 1979, cancer antigen 19-9 (CA 19-9) for pancreatic cancer in 1979, and cancer antigen 125 (CA 125) for ovarian cancer in 1981 . These markers became integrated into clinical practice, though primarily for disease monitoring rather than early detection due to inherent limita tions in sensitivity and specificity.

Classification and Characteristics of Cancer Biomarkers - Cancer biomarkers encompass diverse molecular classes including proteins, nucleic acids, carbohydrates, and cellular components. They can be classified by their chemical nature, biological function, or clinical application. Protein biomarkers represent the most extensively studied category, including enzymes, hormones, and oncofetal antigens. Genomic biomarkers include DNA mutations, copy number variations, and epigenetic modifications such as methylation patterns. Transcriptomic biomarkers comprise various RNA species including messenger RNA and non-coding RNAs. Cellular biomarkers encompass circulating tumor cells and exosomes.

An ideal cancer biomarker should demonstrate high sensitivity (ability to detect true positives) and specificity (ability to identify true negatives), be detectable in easily accessible biological samples, show correlation with tumor burden, and provide sufficient lead time for clinical intervention. However, currently available tumor markers frequently lack these ideal characteristics. Most demonstrate insufficient sensitivity and specificity for early detection, with levels that can be elevated in non-malignant conditions, often resulting in false positive findings and unnecessary biopsies . For instance, CA 19-9 elevations occur not only in pancreatic cancer but also in colorectal, biliary tract, liver, gastric, and lung cancers, as well as non-malignant conditions including liver damage, bile duct obstruction, pancreatitis, and pulmonary fibrosis .

Traditional Protein Biomarkers in Clinical Practice - Several protein biomarkers have achieved regulatory approval and widespread clinical adoption, though predominantly for monitoring rather than screening. Prostate-specific antigen (PSA) represents one of the most utilized tumor markers, employed for prostate cancer screening, despite ongoing controversy regarding overdiagnosis and overtreatment. Alpha-fetoprotein (AFP) serves in hepatocellular carcinoma diagnosis and monitoring, with serum levels above 400 ng/mL highly suggestive of malignancy. Cancer antigen 15-3 (CA 15-3) and HER2/neu facilitate breast cancer monitoring and therapeutic decision-making. The clinical utility of these markers is constrained by their suboptimal performance characteristics for early detection. Cho‘liyeva and colleagues note that while blood tests and genomic testing can identify cancer-related biomarkers, their integration with imaging modalities including ultrasound, magnetic resonance imaging, and computed tomography remains essential for comprehensive evaluation. This multimodal approach reflects the recognition that no single biomarker currently provides sufficient diagnostic accuracy for population-based screening.

Genomic and Epigenetic Biomarkers - The completion of the Human Genome Project and subsequent technological advances have enabled comprehensive characterization of cancer genomes, revealing the molecular alterations underlying malignant transformation. Genetic biomarkers include germline mutations conferring hereditary cancer susceptibility and somatic mutations acquired during tumorigenesis. BRCA1 and BRCA2 mutations exemplify clinically significant germline biomarkers, substantially increasing lifetime risks of breast and ovarian cancers. Population-based genetic testing for such susceptibility genes offers potential for precision prevention through enhanced surveillance and risk-reducing interventions.

Epigenetic alterations, particularly DNA methylation changes, represent promising early detection biomarkers. Methylation of specific gene promoters occurs early in carcinogenesis and can be detected in circulating cell-free DNA. The Epi proColon assay, detecting Septin9 methylation in plasma, achieved FDA approval for colorectal cancer screening in average-risk populations, demonstrating 68% sensitivity and 80% specificity. Similarly, SHOX2 and RASSF1A methylation testing for lung cancer has received regulatory approval in various jurisdictions.

Circulating Tumor DNA and Liquid Biopsy - Liquid biopsy, the analysis of tumor-derived materials in body fluids, has emerged as a transformative approach for early cancer detection. Circulating tumor DNA (ctDNA)—fragments of tumor DNA released into the bloodstream through apoptosis, necrosis, or active secretion—provides a real-time representation of tumor genetics. Thomas Junior and colleagues emphasize that ctDNA and circulating tumor cells have been detected at early stages in several cancer types with high

specificity, aiding risk stratification and, in some cases, identifying clinically actionable molecular features .

The advantages of ctDNA-based approaches include non-invasive sampling, capacity to capture tumor heterogeneity, potential for serial monitoring, and applicability across multiple cancer types. The CancerSEEK assay, combining detection of 16 gene mutations and nine protein markers, demonstrated 69-98% sensitivity across eight cancer types with 99% specificity, though positive predictive value was only 19.4% in screening populations . The Galleri multi-cancer early detection test, utilizing genome-wide methylation analysis, achieved overall sensitivity of 51.5% (67.6% for stages I-III) with 99.5% specificity and 97.1% accuracy in predicting tissue of origin .

DISCUSSION

Integration of Multiple Biomarker Classes - The complexity of cancer biology suggests that single biomarkers will prove insufficient for comprehensive early detection. Multi-analyte panels integrating complementary marker classes offer advantages by capturing different aspects of tumor biology. The THUNDER study, combining cfDNA methylation analysis across multiple cancer types, achieved 75.1% sensitivity and 95.1% specificity, with tissue of origin prediction accuracy of 89.7% . Similarly, the HCCscreen assay integrating mutation detection (TP53, CTNNB1, TERT), methylation analysis (15 genes), and protein markers (AFP, DCP) demonstrated 88% sensitivity and 93% specificity in high-risk populations .

These multi-modal approaches recognize that genomic alterations provide specificity while protein markers offer sensitivity, and that epigenetic changes may occur earlier than mutations in some cancer types. The optimal composition of such panels likely varies by cancer type, clinical context, and target population.

Technological Innovations Enabling Biomarker Discovery - Several technological advances have accelerated biomarker discovery and clinical translation. Next-generation sequencing enables comprehensive genomic profiling at decreasing costs, facilitating identification of recurrent mutations across cancer types. Digital PCR provides absolute quantification of rare nucleic acid targets with unprecedented sensitivity. Mass spectrometry-based proteomics allows simultaneous measurement of hundreds to thousands of proteins. These technologies, combined with advanced bioinformatics and machine learning approaches, enable identification of subtle biomarker signatures that might escape traditional analysis .

Wearable biosensors represent an emerging frontier for continuous biomarker monitoring. The concept of real-time, longitudinal tracking of tumor-associated biomarkers could enable detection of malignancy at its earliest stage by identifying deviations from an individual's

baseline before clinical symptoms appear . Such approaches align with the low index of individuality observed for most tumor markers, emphasizing the importance of personalized reference intervals over population-based thresholds.

Novel Assay Platforms - The indicator cell assay platform (iCAP) represents an innovative approach to blood-based diagnostics that addresses the low signal-to-noise ratio limiting conventional biomarker performance. By using cultured cells as biosensors exposed to patient serum, this platform amplifies cancer-specific signals through cellular response pathways. The lung cancer iCAP (LC-iCAP) achieved 90% sensitivity and 64% specificity with 95% negative predictive value at 25% prevalence when integrated with CT-based features, improving upon standard clinical models for indeterminate pulmonary nodule management . The lung-cancer specific transcriptional response was enriched for hypoxia-responsive genes, implicating HIF1A and HIF2A activity consistent with known lung cancer biology and demonstrating the platform's mechanistic relevance .

Challenges in Clinical Implementation - Despite remarkable progress, significant challenges impede widespread clinical implementation of biomarker-based early detection. Pre-analytical variables including sample collection, processing, and storage substantially impact biomarker measurements, necessitating standardized protocols. Analytical sensitivity requirements for early detection are extremely demanding, as circulating tumor materials may constitute less than 0.1% of total cell-free DNA in early-stage disease . Biological challenges include tumor heterogeneity, which may result in sampling bias even with liquid biopsy approaches. Clonal hematopoiesis of indeterminate potential can produce false-positive results by releasing mutations from non-malignant hematopoietic cells into circulation. The complexity of exosome isolation and characterization limits clinical scalability . Inter-patient variability in biomarker expression complicates interpretation, particularly given the low index of individuality observed for most markers. Longitudinal monitoring may address this challenge but introduces practical barriers related to cost, patient compliance, and healthcare system capacity.

Clinical Validation and Regulatory Pathways - The translation of biomarkers from discovery to clinical application requires rigorous validation through well-designed studies. The PRoBE (Prospective-specimen-collection, Retrospective-blinded-evaluation) design represents a recommended approach, minimizing bias while enabling efficient evaluation. Regulatory approval pathways vary by jurisdiction, with the FDA, European CE marking, and China's NMPA having approved multiple biomarker-based assays for cancer detection .

Demonstrating clinical utility requires evidence that biomarker implementation improves patient outcomes compared to standard care. For screening applications, this necessitates large prospective trials with mortality endpoints, which are costly and time-consuming.

Surrogate endpoints including stage shift (increased proportion of early-stage diagnoses) may accelerate evaluation but require validation as predictors of mortality benefit.

Health Equity Considerations

The global burden of cancer falls disproportionately on low- and middle-income countries, where diagnostic resources are most limited. Patients in low-income countries are 50% less likely to be diagnosed with cancer than patients in high-income countries due to limited accessibility to diagnostic and treatment procedures . Biomarker-based approaches offering simplicity, scalability, and cost-effectiveness could help address this disparity, but only if developed with global implementation in mind.

Point-of-care biomarker platforms, dried blood spot sampling, and centralized testing with result telemedicine delivery represent strategies for expanding access. However, validation studies must include diverse populations to ensure performance characteristics generalize across ethnic and geographic groups. Cost-effectiveness analyses should consider not only assay costs but also the economic benefits of earlier diagnosis, including reduced treatment expenses and preserved productivity.

RESULTS

Performance Characteristics of Established Biomarkers - Analysis of clinically utilized tumor markers reveals consistent patterns in their performance for early detection. The sensitivity of CEA for early-stage colorectal cancer is approximately 40-50%, rising to 70-80% in metastatic disease. CA 125 detects only 50-60% of early-stage ovarian cancers, with false-positive rates of 20% or higher in benign conditions. PSA screening reduces prostate cancer mortality but at the cost of substantial overdiagnosis, with estimates suggesting 20-50% of screen-detected cancers would never have caused clinical symptoms .

These limitations reflect fundamental biological constraints including marker production by non-malignant tissues, variable marker expression across tumors of the same type, and the small size of early lesions relative to total body marker production. The doubling time data presented in Table 1 of comprehensive reviews illustrates this challenge: even aggressive tumors require months to years to reach clinically detectable size, yet marker levels may remain within population reference ranges throughout much of this period .

CONCLUSION

Modern biomarkers have fundamentally transformed the landscape of early cancer detection, offering unprecedented opportunities for non-invasive identification of malignancies at their most treatable stages. The evolution from single protein markers to multi-analyte panels incorporating genomic, epigenomic, transcriptomic, and cellular biomarkers reflects growing understanding of cancer complexity and the limitations of reductionist approaches. Circulating tumor DNA, circulating tumor cells, exosomes, and

microRNAs each provide complementary information about tumor presence, location, and biology. The clinical impact of these advances is increasingly evident. Regulatory approvals for multi-cancer early detection assays, methylation-based screening tests, and miRNA panels demonstrate growing confidence in biomarker performance. Integration with established screening modalities—mammography for breast cancer, low-dose CT for lung cancer, colonoscopy for colorectal cancer—offers opportunities to enhance sensitivity while maintaining specificity. For cancers lacking effective screening methods, including ovarian, pancreatic, and gastric malignancies, biomarker-based approaches may finally provide tools for early detection. However, significant challenges remain before the full potential of biomarker-based early detection can be realized. Standardization of pre-analytical and analytical procedures is essential for reproducible clinical performance. Rigorous validation in diverse populations must precede widespread implementation. Health system infrastructure must adapt to accommodate new testing paradigms, including management of indeterminate results and integration with existing diagnostic pathways. Cost-effectiveness analyses must guide resource allocation, particularly in low- and middle-income countries where cancer burden is highest and healthcare resources most constrained.

Future directions in biomarker development will likely include continued refinement of multi-analyte panels incorporating artificial intelligence for pattern recognition, expansion of wearable and continuous monitoring technologies, and integration of biomarker testing with digital health platforms for result interpretation and clinical decision support. Population-based genetic testing for cancer susceptibility genes may expand beyond current criteria-based approaches, enabling precision prevention through enhanced surveillance and risk-reducing interventions . Novel platforms including cell-based biosensors may address signal-to-noise limitations that have constrained conventional approaches .

The ultimate goal remains clear: detection of cancer at its earliest, most curable stage, when intervention can achieve maximum benefit with minimal morbidity. Modern biomarkers, thoughtfully developed, rigorously validated, and equitably implemented, offer the most promising pathway toward this vision. Realizing this potential will require sustained commitment from researchers, clinicians, industry partners, policymakers, and funders, working collaboratively to translate scientific advances into clinical reality for patients worldwide.

REFERENCES

1. Cho‘liyeva, D., Bazarova, G., & Rizvonqulova, M. (2025). Onkologiya saratonni erta aniqlash usullari. *Modern Science and Research*, 4(6), 1154-1158.
2. Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals. (2025). *Biomolecules*, 15(7), 1011.
3. Thomas Junior, D. S., et al. (2025). The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection. *Exploration of Targeted Anti-tumor Therapy*, 6, 1002314.
4. A multivariate cell-based assay for blood-based diagnostics enhances lung cancer risk stratification. (2025). *medRxiv*.
5. Kamalova, D. D., & Norxujaeva, C. B. (2024). Ko'krak bezi saratonini erta aniqlash: asosiy biomarkerlar va ularning roli. *Universitas Muhammadiyah Sidoarjo Repository*.
6. Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives. (2025). *European Journal of Medical Research*, 30, 760.
7. Development and clinical applications of liquid biopsy assays in cancer screening. (2025). *Translational Cancer Research*.
8. Kamalova, D. D., & Norxujaeva, C. B. (2024). Broadening cancer detection with population-based genetic testing for women. *Universitas Muhammadiyah Sidoarjo Repository*.
9. Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives. (2025). *Springer*.